ArticleCureus2026
Molecular Subtyping, Receptor Concordance, and Magee Score Assessment in Breast Carcinoma: An Immunohistochemical Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast carcinoma is a heterogeneous disease characterized by variable expression of estrogen receptor (ER), progesterone receptor (PR), HER2/neu, and Ki-67, which influence molecular classification and therapeutic decision-making. This study evaluated the immunohistochemical profile of invasive breast carcinoma, assessed receptor concordance between primary tumors and corresponding metastatic deposits, and estimated recurrence risk using Magee score equations. METHODOLOGY: This cross-sectional study was conducted on 30 cases of invasive breast carcinoma. Immunohistochemical expression of ER, PR, HER2/neu, and Ki-67 was evaluated, and molecular subtypes were classified accordingly. Receptor concordance between primary tumors and corresponding metastatic deposits was assessed using McNemar's test for paired categorical data. Magee recurrence scores were calculated to estimate recurrence risk. Descriptive statistics were used to summarize clinicopathological characteristics, and a p-value <0.05 was considered statistically significant.
resultsThirty patients with invasive breast carcinoma were included, with a mean age of 44.8 ± 2.3 years. ER positivity was observed in 23 cases (76.7%), PR positivity in 15 cases (50.0%), and HER2/neu positivity in three cases (10.0%). Luminal A was the predominant molecular subtype, accounting for 22 (73.3%) cases. Among the 19 paired primary and metastatic samples, ER and PR discordance was identified in 14 (73.7%) and 10 (52.6%) cases, respectively, whereas no HER2/neu discordance was observed. Among cases with nodal metastasis, involvement of 1-3 lymph nodes was most frequent, occurring in 11 (57.9%) cases. One patient (5.3%) had distant brain metastasis. H-score analysis demonstrated that ER H-scores of 101-200 and 201-300 were observed in 12 (52.2%) and 10 (43.5%) cases, respectively, whereas PR H-scores of 101-200 and 201-300 were observed in six (40.0%) and eight (53.3%) cases, respectively. Based on aggregate Magee scores, 16 (53.3%) patients were categorized as low risk, nine (30.0%) as intermediate risk, and five (16.7%) as high risk.
conclusionImmunohistochemical profiling revealed a predominance of luminal A tumors and substantial discordance in ER and PR expression between primary tumors and metastatic deposits. Magee score assessment demonstrated that most patients belonged to the low-risk category, supporting its potential utility as a cost-effective prognostic tool in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.